/
Other
Immunogenicity
88
Pipeline Programs↗
119
Active Trials↗
133
Companies Involved↗
Immunogenicity is a moderately active landscape with 88 programs across 133 companies. The most active players are LiteVax BV, Amicus Therapeutics, Sanofi. 25 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical8
Phase 137
Phase 218
Phase 325
Approved
No programs
Analysis
Modality Breakdown
36programs
Small molecule1953%
Vaccine1233%
Monoclonal antibody26%
Protein / enzyme26%
RNA therapy13%
Modality classified for 100% of 88 pipeline programs.
Analysis
Trial Status
1,617
clinical trials
Completed1,286 · 80%
Unknown status126 · 8%
Terminated49 · 3%
Active, not recruiting48 · 3%
Recruiting39 · 2%
Withdrawn34 · 2%
Other35 · 2%
Clinical Trials
Trial Activity
1617 trials
Immunogenicity of 9-valent HPV Vaccine
Recruiting·—·Phase 4·NCT05439083·120 enrolled
Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC
Recruiting·—·Phase 3·NCT06844487·344 enrolled
Page 1 of 108
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)